Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 4/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23909047 | 0.75 | S1PR2 (0.71) | S1PR2L3MBTL1 | |
| SCHEMBL23908849 | 0.61 | S1PR2 (0.70) | S1PR2L3MBTL1 | |
| SCHEMBL21631643 | 0.59 | EPHX2 (0.44) | S1PR2PDE4DPDE4B | |
| SCHEMBL23908853 | 0.59 | S1PR2 (1.00) | S1PR2L3MBTL1 | |
| SCHEMBL23908877 | 0.59 | S1PR2 (1.00) | S1PR2L3MBTL1 | |
| SCHEMBL23208619 | 0.57 | UCHL1 (0.32) | S1PR2PDE4DPDE4B | |
| SCHEMBL24879334 | 0.55 | ADORA3 (0.42) | L3MBTL1 | |
| SCHEMBL19207534 | 0.54 | ALDH1A1 (0.59) | POLB | |
| SCHEMBL5505741 | 0.54 | PDE4A (0.53) | PDE4DPDE4BKMT2APDE4APDE4C | |
| SCHEMBL28235173 | 0.54 | CREBBP (0.43) | CREBBPPOLBKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |